Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
•
Hospital Medicine
Do you routinely check cefepime levels in patient's with suspected cefepime-induced neurotoxicity?
Answer from: at Community Practice
No. I would never get the result soon enough. I just change the antibiotic.
Sign in or Register to read more
23169
Related Questions
When should antibiotics be discontinued for an immunocompetent patient with signs of meningoencephalitis who undergoes an LP without prior administration of antibiotics and the CSF shows a neutrophilic pleocytosis, negative Gram stain, negative PCR Panel, and negative CSF culture at day 3-5?
Are there situations where you would consider treating E faecalis or E faecium that grows from a respiratory culture?
What is your preferred agent and duration to treat an epidural abscess due to azole-resistant candida species?
What would be an ideal time to place a VP shunt in a patient with candida meningitis/ventriculitis?
Do you recommend procalcitonin to help convince other providers to stop antibiotics in patients with pneumonia in whom a non-infectious diagnosis is strongly suspected?
Under what circumstances do you consider valacyclovir for the management of VZV disease of the CNS?
What factors should be prioritized when deciding the timing of CIED extraction in patients with high surgical risk or multiple comorbidities?
How do you manage recurrent C diff which occurs shortly after FMT when alternate etiologies of diarrhea have been excluded and patient is responding to C diff-directed therapies?
For patients with candida species osteomyelitis who have undergone extensive surgical debridement, do you routinely still recommend 6-12 months of antifungal therapy or opt for a shorter duration?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?